NCT02177825终止2 期
Phase II Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
St. Justine's Hospital1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2014年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Demonstrate the clinical benefit of imatinib in a pediatric patient population with progressing and metabolically active plexiform NFs
研究概览
简要总结
This phase II trial will test the hypothesis that inhibition of c-kit signalling pathways in pediatric patients with Neurofibromatosis Type I(NF-1) and progressing plexiform neurofibroma will result in objective reduction and/or inhibition of plexiform neurofibromas progression.
This will be a Phase II study of imatinib mesylate given orally. Patients with stable or responding disease may receive the drug for a period not exceeding one year.
详细描述
Clinical objectives
- Demonstrate the clinical benefit of imatinib in a pediatric patient population with progressing and metabolically active plexiform neurofibromas (NF)
- Demonstrate the need or not to pursue treatment for more than a year in responders to imatinib
Biological studies objectives
- Identify biological markers of plexiform neurofibroma progression and response to treatment
- Identify biological markers of mast cell responses to imatinib, given that mast cells are required for tumorigenesis and are a target for imatinib
Imaging studies objectives
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age Greater than or equal to 2 years and up to 21 years of age at time of study enrolment
- •Diagnosis Patients with NF1 and an inoperable plexiform NFs that has the potential to cause significant morbidity.
- •Patients must have measurable disease by magnetic resonance imaging (MRI) and progressive plexiform neurofibroma(s) with or without clinical symptoms.
- •Patients must have a recent FDG-PET scan imaging study done in the last 3 months before being offered participation to the study
- •Surgery/Residual disease: Patients are only eligible if complete tumor resection is not feasible, or if a patient with a surgical option refuses surgery. Evidence of recurrent or progressive disease is NOT necessary. Patients must be at least 21 days from surgery, if performed, prior to receiving their first dose of study drug
- •Performance level Patients must have a Karnofsky of > 70% or Lansky of >50% and a life expectancy of > 6 months.
- •Previous use of imatinib is permitted if there was no progressive disease during treatment.
- •Prior therapy Patients must be at least 28 days without any treatment before enrolment in this study.
- •Patient is free of another primary malignancy except if the other primary malignancy neither currently clinically significant nor requiring active intervention.
- •Organ function requirement
- •Creatinine < 1.5 x upper limit of normal (ULN)
- •Total bilirubin < 1.5 x ULN and SGOT and SGPT < 2.5 x ULN
- •ANC > 1.5 x 109/L and Platelets > 100 x 109/L
- •Reproductive potential Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
排除标准
- •Patient has received any other investigational agents within 28 days of first day of study drug dosing.
- •Patient with rapidly progressing disease may be enrolled before the 28 days period. In these cases, only the study chair can take this decision.
- •Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.
- •Female patients who are pregnant or breast-feeding.
- •Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection)
- •Patient has a known brain metastasis. Non-specific central nervous system (CNS) changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies.
- •Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
- •Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
- •Patient received chemotherapy within 4 weeks prior to study entry.
- •Patient previously received radiotherapy to greater than or equal to 25% of the bone marrow within 24 months.
- •Patient had a major surgery within 2 weeks prior to study entry.
- •Patient with any significant history of non-compliance to medical regimens.
- •Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI.
研究组 & 干预措施
Imatinib Mesylate
Experimental
Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
干预措施: Imatinib Mesylate (Drug)
结局指标
主要结局
Demonstrate the clinical benefit of imatinib in a pediatric patient population with progressing and metabolically active plexiform NFs
时间窗: 12 months
Time to tumor progression as assessed by volumetric MRI and FDG-PETScan analysis at baseline, after 3, 6, 9, and 12 months on therapy.
次要结局
- Changes in NF1 biomarkers after treatment with imatinib(12 months)
研究者
Dr Perreault
Neurologist
St. Justine's Hospital
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Study of Imatinib in Children With Neurofibromatosis and Airway TumorsNeurofibroma, PlexiformNCT03688568Indiana University
已完成
2 期
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansDermatofibrosarcoma ProtuberansAdult FibrosarcomaRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaNCT00084630National Cancer Institute (NCI)40
已完成
2 期
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous NeurofibromaCutaneous NeurofibromaOptic Nerve GliomaNeurofibromatosis Type 1NCT02839720National Cancer Institute (NCI)11
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
进行中（未招募）
2 期
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasPlexiform NeurofibromaNeurofibromatosis Type 1 (NF1)NCT03962543SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany114